Preimplantation genetic screening (PGS) for aneuploidies in patients with advanced maternal age undergoing in vitro fertilization.

Gepubliceerd: 15-08-2005 Laatst bijgewerkt: 18-08-2022

To determine whether IVF/ICSI combined with PGS in patients with advanced maternal age, i.e. women between 35 and 41 years of age, is a cost-effective alternative compared to IVF/ICSI without PGS.

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON25213

Bron
NTR

Verkorte titel
N/A

Aandoening

Subfertility/infertility in women with advanced maternal age.

Ondersteuning

Primaire sponsor: Academic Medical Center
Overige ondersteuning: Netherlands Organisation for Health Research and Development (ZonMw)

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Ongoing pregnancy rate.

Toelichting onderzoek

Achtergrond van het onderzoek

A double-blind randomized controlled trial is conducted to determine whether IVF/ICSI combined with PGS in patients with advanced maternal age, i.e. women between 35 and 40 years of age, is a cost-effective alternative compared to IVF/ICSI without PGS.
Patients are allocated at random to one of two treatment arms:
IVF/ICSI with PGS (selection of embryos based on normal number of studied chromosomes) or IVF/ICSI without PGS (selection of embryos based on morphology). Primary outcome is ongoing pregnancy. Secondary outcomes are time to pregnancy, clinical pregnancy rate, pregnancy outcome and implantation rate.

Doel van het onderzoek

To determine whether IVF/ICSI combined with PGS in patients with advanced maternal age, i.e. women between 35 and 41 years of age, is a cost-effective alternative compared to IVF/ICSI without PGS.

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

Patients are allocated at random to one of two treatment arms: IVF/ICSI with PGS (selection of embryos based on normal number of studied chromosomes) or IVF/ICSI without PGS (selection of embryos based on morphology). A maximum of two embryos will be transferred, according to the ESHRE-guidelines. In both treatment arms three treatment-cycles will be offered.

Contactpersonen

Publiek

Academic Medical Center (AMC), Center For Reproductive Medicine,
P.O. Box 22660
Sebastiaan Mastenbroek
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5663090

Wetenschappelijk

Academic Medical Center (AMC), Center For Reproductive Medicine,
P.O. Box 22660
Sebastiaan Mastenbroek
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5663090

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Women between 35 and 41 years of age, undergoing IVF (in vitro fertilization) or ICSI (intracytoplasmatic sperm injection).

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

N/A

Onderzoeksopzet

Opzet

Type: Interventie onderzoek

Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Geneesmiddel

Deelname

Nederland

Status:	Werving gestopt
(Verwachte) startdatum:	01-05-2003
Aantal proefpersonen:	372
Type:	Werkelijke startdatum

Ethische beoordeling

Positief advies

Datum:	15-08-2005
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL56
NTR-old	NTR84
Ander register	: ZON-MW 945-03-013
ISRCTN	ISRCTN76355836

Resultaten

Samenvatting resultaten
N Engl J Med. 2007 Jul 5;357(1):9-17. Epub 2007 Jul 4.